Topics

AZ's acalabrutinib gains breakthrough therapy designation for CLL

06:40 EDT 15 Aug 2019 | SmartBrief

AstraZeneca's Calquence, or acalabrutinib, gained breakthrough therapy designation as a treatment for chronic lymphocytic leu -More

Original Article: AZ's acalabrutinib gains breakthrough therapy designation for CLL

NEXT ARTICLE

More From BioPortfolio on "AZ's acalabrutinib gains breakthrough therapy designation for CLL"

Quick Search

Relevant Topic

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...